A peptide with a dual mechanism of action – it dissolves the bacterial membrane and activates the immune system – could be an effective weapon against microorganisms that have evolved ways to evade antibiotics, as superbugs do. Scientists at the University of Pennsylvania (UPenn) have designed stable synthetic peptides that activate mast cell receptors, which are cells involved in the innate and adaptive immune response. This dual approach eliminates bacteria and recruits neutrophils to finish the job.
Gemvax & Kael Co. Ltd. has identified peptides reported to be useful for the treatment of age-related macular degeneration (AMD), cerebral amyloid angiopathy and Alzheimer’s disease.
Caregen Co. Ltd. has identified peptides reported to be useful for the treatment of cartilage injury, fracture, intervertebral disc herniation, degenerative intervertebral disc disorder, osteoarthritis, osteomalacia and muscular injury.
Caregen Co. Ltd. has described peptides reported to be useful for the treatment of cartilage injury, fracture, intervertebral disc herniation, degenerative intervertebral disc disorder, osteoarthritis, osteomalacia and muscular injury.
Seinda Pharmaceutical Corp. has disclosed peptides reported to be useful for the treatment of corneal epithelial defect, corneal neovascularization and dry eye.
Researchers at Mossakowski Medical Research Centre at the Polish Academy of Sciences (PAS) and The University of Warsaw have divulged peptides reported to be useful for the treatment of pain.
Researchers from Almirall SA and affiliated organizations reported the discovery and preclinical characterization of LAS-200813, a novel peptide inhibitor of the Keap1-Nrf2 protein-protein interaction.
